Free Trial
LON:TRX

Tissue Regenix Group (TRX) Share Price, News & Analysis

Tissue Regenix Group logo
GBX 32.80 +1.80 (+5.81%)
As of 05/2/2025 12:26 PM Eastern

About Tissue Regenix Group Stock (LON:TRX)

Key Stats

Today's Range
30
32.80
50-Day Range
31
45.90
52-Week Range
30
75
Volume
214,611 shs
Average Volume
47,258 shs
Market Capitalization
£29.57 million
P/E Ratio
N/A
Dividend Yield
4.12%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care. In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

Receive TRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter.

TRX Stock News Headlines

Tissue Regenix Group Regulatory News
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Tissue Regenix Group Share Chat (TRX)
Tissue Regenix Group PLC (LSW.BE)
Tissue Regenix Group plc (TRX.L)
See More Headlines

TRX Stock Analysis - Frequently Asked Questions

Tissue Regenix Group's stock was trading at GBX 60 at the start of the year. Since then, TRX stock has decreased by 45.3% and is now trading at GBX 32.80.
View the best growth stocks for 2025 here
.

Tissue Regenix Group plc (LON:TRX) posted its earnings results on Wednesday, September, 2nd. The company reported ($0.16) EPS for the quarter. Tissue Regenix Group had a negative trailing twelve-month return on equity of 2.87% and a negative net margin of 3.46%.

Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tissue Regenix Group investors own include Lloyds Banking Group (LLOY), Argos Therapeutics (ARGSQ), FuelCell Energy (FCEL), TransEnterix (TRXDW), Swedbank AB (publ) (SWDBY), Trevena (TRVN) and Barrick Gold (ABX).

Company Calendar

Last Earnings
9/02/2020
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
Precious Metals
Current Symbol
LON:TRX
CIK
N/A
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
65.31
P/E Growth
N/A
Net Income
£-1,105,225.70
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£31.98 million
Cash Flow
GBX 5.75 per share
Price / Cash Flow
5.70
Book Value
GBX 41.58 per share
Price / Book
0.79

Miscellaneous

Free Float
N/A
Market Cap
£29.57 million
Optionable
Not Optionable
Beta
1.61
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (LON:TRX) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners